Sanofi Targets Bronchiolitis Awareness Amid Beyfortus Slump
A new PSA video urges parents to recognize bronchiolitis, a serious RSV complication in young children.
Updated on Nov. 4, 2026 in Asthma
Live Poll
Would you know when a child's cold needs a doctor's visit right away?
Sanofi has released a PSA video raising awareness of bronchiolitis, a chest infection that can develop from a progressing RSV infection in young children. The campaign comes as Beyfortus revenue fell 15.4% to €631 million in the company's third quarter financials.
Why it matters
Bronchiolitis is the leading cause of hospitalization in infants under one, so recognizing its progression from a typical cold matters for early care. The awareness push also comes as Sanofi seeks to strengthen demand for Beyfortus ahead of the new RSV season.
Beyfortus revenue fell 15.4% to €631 million in Sanofi's third quarter financials, with U.S. revenue down 39.3% year-over-year to €240 million. The filings do not explain the drivers of the decline, and the effect of the bronchiolitis awareness effort on future sales has not been reported.
The players
Sanofi
A French multinational pharmaceutical company that markets Beyfortus alongside AstraZeneca and is the source of the bronchiolitis awareness campaign.
Keke Palmer
An American actress and singer who served as a paid spokesperson for a Sanofi Beyfortus spot released in September.
Food and Drug Administration
The U.S. federal agency that regulates drugs and issued an untitled letter to Sanofi over its promotion of Beyfortus.
The details
Sanofi's PSA video has parents listen to recorded breathing sounds of a baby with bronchiolitis, asking them what the sound means to them. The recording is not from a real child, and no children were used in the production.
Timeline
- November 4, 2026: Sanofi publishes the bronchiolitis PSA video.
- Late October 2026: Sanofi releases third quarter financials showing the Beyfortus decline.
- September 2026: A Keke Palmer spot for Beyfortus is released.
- Summer 2026: The U.K. PMCPA reprimands Sanofi over claims about Pfizer's RSV vaccine.
- July 2026: The FDA issues an untitled letter criticizing Beyfortus promotion.
Health Landscape
The campaign follows the FDA's July untitled letter criticizing Sanofi's promotion of Beyfortus, a monoclonal antibody for RSV prevention in infants. It reflects a broader industry pattern in which RSV products compete for pediatric prescribing while regulators scrutinize their marketing claims.
Parents of infants should know that bronchiolitis can advance from a typical cold into a deeper chest infection over several days. Recognizing worsening breathing in a young child can help families seek timely medical evaluation.
The takeaway
Parents should watch for signs that a cold is progressing in young children, since bronchiolitis can follow RSV infection. Early recognition of worsening symptoms may help prompt timely care.
Further reading
Explore more on Asthma for context on childhood respiratory conditions.
Source note: This article includes information reported by FiercePharma.
Live Poll
Would you know when a child's cold needs a doctor's visit right away?
